Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients

doi:10.3748/wjg.v18.i39.5570

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3965)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

431

HTML

3022

Figures (1-2)

261

Tables (1-4)

251

Sum=3965

Oct 21, 2012 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 21, 2012; 18(39): 5570-5575
Published online Oct 21, 2012. doi: 10.3748/wjg.v18.i39.5570

Table 1 Baseline characteristics of the patients with hepatitis B virus genotype C

	HBeAg-negative group	HBeAg-positive group	P value
No.	26	24	NS
Age (yr)	57.2 (35-80)	44.2 (35-71)	< 0.01
Gender, M:F	15:16	16:11	NS
Diseases, CH:LC/HCC	21:5	23:1	NS
ALT (IU/mL)	38 (13-950)	102 (812-602)	< 0.01
Platelet counts (× 10⁴/mL)	18.6 (3.4-4.9)	18.0 (8.4-26.8)	NS
Albumin (mg/dL)	4.3 (3.4-4.9)	4.2 (2.3-5.0)	NS
Serum HBV DNA level	5.1 (3.9-8.8)	7.6 (5.6-8.8)	< 0.01
(log copies/mL)	5.1 (3.9-8.8)	7.6 (5.6-8.8)	< 0.01

All data are shown by median (range). HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; CH: Chronic hepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; NS: Not significant.

Table 2 Clinical and virological results among the hepatitis B e antigen-negative group, the rapid-responders, and the slow-responders in the hepatitis B e antigen-positive group during 2 years of entecavir therapy

Characteristics	HBeAg-negative group	HBeAg-positive group		P value
Characteristics	(n = 26)	RR (n = 14)	SR (n = 10)	RR vs SR
<Baseline data>
Age	58 (35-80)	45 (34-68)	43 (31-71)	NS
Gender (male:female)	13:13	9:5	6:4	NS
Disease (CH:LC/HCC)	21:5	13:1	6:4	NS
ALT (IU/L)	38 (13-950)	131 (12-602)	31 (13-108)	0.02
Platelet count (× 10⁴/mL)	18.6 (3.4-35.1)	17.1 (8.4-22.4)	20.0 (11.0-26.8)	NS
Albumin (mg/dL)	4.3 (3.4-4.9)	4.0 (2.3-5.0)	4.4 (3.7-4.6)	NS
HBV genotype C	100%	100%	100%	NS
HBV DNA (log copies/mL)	5.1 (3.9-8.8)	7.4 (5.6-8.8)	8.3 (7.1-8.8)	NS
qHBsAg (log IU/mL)	3.17 (0.70-4.58)	3.63 (1.68-4.34)	4.57 (4.35-4.76)	< 0.01
HBcrAg (log U/mL)	3.6 (3.0-> 6.8)	> 6.8 (6-> 6.8)	> 6.8 (> 6.8-> 6.8)	NS
Pre-C mutation (%)	83.3	0	0	NS
Core promoter mutation (%)	58.3	57.1	50.0	NS
<At year 2 during therapy>
HBV DNA (log copies/mL)	0.0 (0.0-2.7)	2.1 (0.0-2.1)	3.5 (3.1-6.9)	-
ALT (IU/L)	18 (9-75)	17.5 (10-31)	23 (13-37)	NS
HBeAg seroconversion	-	23.50%	0%	NS
HBsAg seroclearance	0%	0%	0%	NS
qHBsAg (log IU/mL)	2.91 (0.62-3.9)	3.25 (1.70-3.92)	4.12 (3.23-4.47)	0.01
HBcrAg (log U/mL)	3.0 (3.0-5.4)	5.9 (4.0-> 6.8)	> 6.8 (5.2-> 6.8)	< 0.01
Resistant mutations against entecavir	UDL	UDL	0%	-

HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; CH: Chronic hepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; UDL: Under the detection limit; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; qHBsAg: Quantitation of HBsAg level; HBcrAg: HBV core-related antigen; NS: Not significant; RR: Rapid-responder; SR: Slow-responder.

Table 3 Drug resistant mutations in the slow-responders at year 2

Patient	Age (yr)	Gender	Previous therapy	HBV genotype	Drug resistant mutations against
					Lam	Lam	Lam/Ade	Ade	Ent	Ent	Ent
					L180	M204	A181	N236	T184	S202	M205
1	52	Male	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
2	35	Male	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
3	68	Male	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
4	56	Female	No	C	Wild	M204I	Wild	Wild	Wild	Wild	Wild
5	36	Female	No	C	Wild	M204I	Wild	Wild	Wild	Wild	Wild
6	45	Male	No	C	Wild	M204I	Wild	Wild	Wild	Wild	Wild
7	35	Male	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
8	67	Female	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
9	39	Male	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild
10	44	Female	No	C	Wild	Wild	Wild	Wild	Wild	Wild	Wild

Lam: Lamivudine; Ade: Adefovir; Ent: Entecavir; HBV: Hepatitis B virus.

Table 4 Pretreatment clinical and virological characteristics between hepatitis B virus DNA-negative and -positive group at year 2 during entecavir therapy

Characteristics	HBV DNA-negative group	HBV DNA-positive group	P value
Characteristics	(n = 19)	(n = 31)	Univariate analysis	Multivariate analysis
Age	51 (31-73)	52 (32-80)	NS
Gender (male:female)	12:7	20:11	NS
Disease (CH:LC/HCC)	17:2	27:4	NS
ALT (IU/L)	36 (12-366)	108 (13-602)	0.03	NS
Platelet counts (× 10⁴/mL)	19.0 (8.8-35.1)	17.8 (3.4-26.8)	NS
Albumin (mg/dL)	4.35 (3.84-4.85)	4.14 (2.28-4.72)	NS
HBV genotype (B:C:others)	0:19:0	0:31:	NS
HBeAg status (positive:negative)	3:16	21:10	< 0.01	NS
HBV DNA (log copies/mL)	5.1 (3.1-7.4)	7.6 (3.7-8.8)	< 0.01	NS
qHBsAg level (log IU/mL)	3.31 (1.90-4.08)	4.20 (3.06-4.87)	< 0.01	0.03
HBcrAg level (log U/mL)	3.45 (3.0-> 6.8)	> 6.8 (3.0-> 6.8)	NS
Pre-C mutation (%)	75.0	43.3	NS
Core promoter mutation (%)	37.5	60.0	NS

CH: Chronic hepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; qHBsAg: Quantitation of hepatitis B surface antigen level; HBcrAg: HBV core-related antigen; NS: Not significant.

Citation: Orito E, Fujiwara K, Kanie H, Ban T, Yamada T, Hayashi K. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients. World J Gastroenterol 2012; 18(39): 5570-5575
URL: https://www.wjgnet.com/1007-9327/full/v18/i39/5570.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i39.5570